Clinical trials: Inflammatory Skin Disease
Psoriasis Vulgaris
Predicting Inflammatory Skin Disease Response to IL-23 Blockade
This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.
- Trial name
- NCT04541329
- Testing
- Tildrakizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Acne Vulgaris
Efficacy of Manuka Honey Nano-Formulation in the Treatment of Acne Vulgaris
The present study aims to manufacture manuka honey-loaded nano-formulation using natural materials as a potent tissue-healing remedy and compare it to commercially available antimicrobial therapy in order to reduce the severity…
- Trial name
- NCT06175819
- Testing
- Manuka honey( MgO 850, UMF+20) loaded nano-formulation
- Volunteers
- 102 people
- Sponsor
- Al-Azhar University
Breast Cancer
Anti-Inflammatory Diet in BRC Patients on Aromatase Inhibitors
This project aims to decrease undesirable side effects and increase qulaity of life of aromatase inhibitors therapy in breast cancer survivors, by anti-inflammatory diet or supplementation.
- Trial name
- AID (NCT06214598)
- Testing
- Supplement, AI diet
- Where
- 2 sites in Serbia
- Volunteers
- 90 people
- Sponsor
- University of Belgrade
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Systemic Sclerosis (SSc), Inflammatory Myopathy
- Trial name
- NCT07104721
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Breast Cancer
Chemotherapy Induced Cognitive Impairment
Chemotherapy is toxic and challenges everyone differently. Most chemotherapy side-effects are known and well documented. However, the phenomenon of "chemo fog" also known as "chemobrain" has not been fully investigated and is…
- Trial name
- CONCERT (NCT05740787)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Aberdeen
Breast Cancer Female NOS, Tubular Breast Cancer Stage II
Denosumab as an add-on Neoadjuvant Treatment (GeparX)
Pharmacologic inhibition of RANKL attenuates the development of mammary carcinoma and inhibits metastatic progression in multiple mouse models.
- Conditions
- Breast Cancer Female NOS, Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Invasive Ductal Breast Cancer
- Trial name
- GeparX (NCT02682693)
- Testing
- Denosumab, nab-Paclitaxel, Epirubicin
- Where
- Germany
- Volunteers
- 780 people
- Sponsor
- GBG Forschungs GmbH
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)
PREVENER is a randomized, open-label, multicenter, phase IV clinical trial designed to evaluate the efficacy and safety of a carotid ultrasound-based strategy for the primary prevention of cardiovascular events in patients with…
- Conditions
- Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Axial Spondy, Systemic Lupus Erythematosus (SLE)
- Trial name
- PREVENER (NCT07611747)
- Testing
- Carotid Ultrasound, High-intensity lipid-lowering therapy, Standard care according to ESC 2021 guidelines
- Where
- 17 sites in Spain
- Volunteers
- 1,944 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Psoriatic Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
This study includes two periods. The main objective of Period 1 is to compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo and versus adalimumab (Humira®) in participants with moderately to…
- Trial name
- SELECT - PsA 1 (NCT03104400)
- Testing
- Adalimumab, Upadacitinib
- Where
- 345 sites in United States, Argentina and 44 more
- Volunteers
- 1,705 people
- Sponsor
- AbbVie
Major Depressive Disorder, Rheumatoid Arthritis
Clinical Study of Escitalopram Oxalate Combined With taVNS in Depression and Concomitant Inflammatory Symptoms
This study is expected to include 90 patients with major depressive disorder and rheumatoid arthritis as study subjects.Randomly divided into 3 groups: drug + VNS stimulation group, drug + sham stimulation group and drug group…
- Trial name
- NCT04037111
- Testing
- Transcutaneous electrical vagus nerve stimulation, drug treatment
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Xijing Hospital
Breast Cancer
Neoadjuvant Treatment of Breast Cancer
Study Aims 1. To measure the clinic response rates in patients with breast cancer more than 2 cm and/or lymph node positive breast cancer treated with 2-4 cycles of biweekly doxorubicin, cyclophosphamide with…
- Trial name
- NCT00254592
- Testing
- Doxorubicin, Cyclophosphamide, Carboplatin
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of California, Irvine
Psoriatic Arthritis
Sex and Gender-based Analysis of the Effectiveness of Advanced Therapies in Psoriatic Arthritis
Sex and gender are important factors that influence treatment response in PsA. The goal of this multi-centre observational study is to understand how sex and gender influence response to advanced therapies in psoriatic arthritis…
- Trial name
- SAGE-PsA (NCT05954364)
- Where
- Canada
- Volunteers
- 540 people
- Sponsor
- Women's College Hospital
Dermatitis, Photocontact
Multi-Centre European Photopatch Test Study
It is known that people can develop an allergic skin reaction to a substance which is placed on the skin and then subjected to sunlight. This process is called Photocontact allergic dermatitis.
- Trial name
- NCT00530387
- Testing
- 19 organic sunscreen filters and 5 topical NSAIDs
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- NHS Tayside
Atopic Dermatitis
Exploratory Study of the Cutaneous Penetration of Biodegradable Polymeric Microparticles in Atopic Dermatitis
This proof of concept study aims to assess in patients suffering from atopic dermatitis if polymeric microparticles reach the pilosebaceous follicles of inflamed skin.
- Trial name
- MicroIskin (NCT02369432)
- Testing
- Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy
- Where
- France
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety…
- Trial name
- NCT02900664
- Testing
- PDR001, ACZ885, CJM112
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 283 people
- Sponsor
- Novartis Pharmaceuticals
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression
- Trial name
- ENDURE (NCT01090310)
- Testing
- AIN457
- Where
- 35 sites in United States, Brazil and 6 more
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Breaking Implicit Bias Habits: An Individuation Pilot Study In Rheumatology
The first aim of this study is to test the efficacy of a real-time provider-based individuation intervention to improve the receipt of high-quality rheumatic disease care among Black/African American and lower socioeconomic…
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Inflammatory Arthritis, Osteoarthritis
- Trial name
- NCT05116163
- Testing
- Individuation Intervention plus implicit bias educational modules, Implicit bias educational modules
- Where
- 2 sites in United States
- Volunteers
- 201 people
- Sponsor
- Brigham and Women's Hospital
Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy
This phase II trial studies how well pembrolizumab works in treating patients with hormone receptor positive inflammatory breast cancer that has not spread to other parts of the body, who are receiving hormone therapy and did not…
- Conditions
- Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Prognostic Stage IIIB Breast Cancer AJCC v8
- Trial name
- NCT02971748
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Rheumatic Disease
Heated Pool Exercise Groups for Patients With Rheumatic Diseases
The purpose of this study is to investigate the effects of heated pool group exercises for patients with inflammatory rheumatic diseases with regard to symptoms (pain, fatigue, stiffness and ability to carry out daily activities).
- Trial name
- NCT01755832
- Testing
- Pool exercise
- Where
- Norway
- Volunteers
- 36 people
- Sponsor
- National Resource Center for Rehabilitation in Rheumatology
Crohn Disease, Ulcerative Colitis
Safety and Efficacy of Fecal Microbiota Transplantation
The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease…
- Conditions
- Crohn Disease, Ulcerative Colitis, Celiac Disease, Irritable Bowel Syndrome
- Trial name
- NCT04014413
- Testing
- Fecal Microbiota Transplantation
- Where
- Hong Kong
- Volunteers
- 450 people
- Sponsor
- Chinese University of Hong Kong
Systemic Juvenile Idiopathic Arthritis (SJIA)
ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab
The purpose of this study was to evaluate the efficacy observed with canakinumab dose reduction in a subgroup of patients in the extension study CACZ885G2301E1.
- Trial name
- ß-SPECIFIC 4 (NCT02296424)
- Testing
- ACZ885 150 mg (Canakinumab)
- Where
- 50 sites in United States, Austria and 14 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.